Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law
Evofem Biosciences (OTCID: EVFM) announced that Illinois has passed House Bill 3489, allowing pharmacists to prescribe non-hormonal and emergency contraceptives, including PHEXXI®, effective January 1, 2026.
The legislation positions Illinois alongside 30 other states and DC in permitting pharmacist-prescribed contraceptives. PHEXXI, FDA-approved in May 2020, is a hormone-free vaginal gel contraceptive that can be used regardless of BMI and showed increased sexual satisfaction in clinical trials.
The law, introduced by Representative Michelle Mussman and sponsored by Senator Rachael Ventura, aims to expand contraceptive access and choices for Illinois residents.
Evofem Biosciences (OTCID: EVFM) ha annunciato che l'Illinois ha approvato il disegno di legge House Bill 3489, consentendo ai farmacisti di prescrivere contraccettivi non ormonali e da emergenza, compreso PHEXXI®, a partire dal 1º gennaio 2026.
La normativa mette l'Illinois al pari di altri 30 stati e del Distretto di Columbia che permettono la prescrizione di contraccettivi da parte dei farmacisti. PHEXXI, approvato dalla FDA nel maggio 2020, è un gel vaginale privo di ormoni che può essere usato indipendentemente dal BMI e che negli studi clinici ha mostrato un aumento della soddisfazione sessuale.
La legge, introdotta dalla rappresentante Michelle Mussman e patrocinata dalla senatrice Rachael Ventura, punta ad ampliare l'accesso e le opzioni contraccettive per i residenti dell'Illinois.
Evofem Biosciences (OTCID: EVFM) anunció que Illinois aprobó la House Bill 3489, permitiendo a los farmacéuticos prescribir anticonceptivos no hormonales y de emergencia, incluido PHEXXI®, a partir del 1 de enero de 2026.
La legislación sitúa a Illinois junto a otros 30 estados y el Distrito de Columbia que permiten la prescripción de anticonceptivos por parte de farmacéuticos. PHEXXI, aprobado por la FDA en mayo de 2020, es un gel vaginal sin hormonas que se puede usar independientemente del IMC y que en ensayos clínicos mostró un aumento en la satisfacción sexual.
La ley, presentada por la representante Michelle Mussman y patrocinada por la senadora Rachael Ventura, busca ampliar el acceso y las opciones anticonceptivas para los residentes de Illinois.
Evofem Biosciences (OTCID: EVFM)는 일리노이가 House Bill 3489를 통과시켜 약사들이 비호르몬 및 응급 피임약(PHEXXI® 포함)을 처방할 수 있도록 했다고 발표했으며, 이 조치는 2026년 1월 1일부터 시행됩니다.
이 법안으로 일리노이는 약사가 피임약을 처방할 수 있도록 허용한 다른 30개 주 및 컬럼비아 특별구와 함께 하게 됩니다. PHEXXI는 2020년 5월 FDA 승인을 받은 호르몬 무함유 질내 젤로, BMI와 관계없이 사용할 수 있으며 임상시험에서 성적 만족도가 향상된 것으로 나타났습니다.
이 법은 미셸 머스먼(Michelle Mussman) 하원의원이 도입하고 레이첼 벤투라(Rachael Ventura) 상원의원이 후원했으며, 일리노이 주민들의 피임 접근성과 선택을 확대하는 것을 목표로 합니다.
Evofem Biosciences (OTCID: EVFM) a annoncé que l'Illinois a adopté la House Bill 3489, autorisant les pharmaciens à prescrire des contraceptifs non hormonaux et d'urgence, y compris PHEXXI®, à compter du 1er janvier 2026.
Cette législation place l'Illinois aux côtés de 30 autres États et du district de Columbia qui permettent la prescription de contraceptifs par les pharmaciens. PHEXXI, approuvé par la FDA en mai 2020, est un gel vaginal sans hormones pouvant être utilisé indépendamment de l'IMC et ayant montré une augmentation de la satisfaction sexuelle dans les essais cliniques.
La loi, introduite par la représentante Michelle Mussman et parrainée par la sénatrice Rachael Ventura, vise à élargir l'accès aux contraceptifs et les choix disponibles pour les résidents de l'Illinois.
Evofem Biosciences (OTCID: EVFM) gab bekannt, dass Illinois den House Bill 3489 verabschiedet hat, der es Apothekern erlaubt, nicht-hormonelle und Notfallverhütungsmittel, einschließlich PHEXXI®, zu verschreiben, wirksam ab dem 1. Januar 2026.
Mit dieser Gesetzgebung reiht sich Illinois neben 30 weiteren Bundesstaaten und dem District of Columbia ein, die die Verschreibung von Verhütungsmitteln durch Apotheker gestatten. PHEXXI, von der FDA im Mai 2020 zugelassen, ist ein hormonfreies vaginales Gel, das unabhängig vom BMI verwendet werden kann und in klinischen Studien eine erhöhte sexuelle Zufriedenheit zeigte.
Das Gesetz, eingebracht von Abgeordneter Michelle Mussman und unterstützt von Senatorin Rachael Ventura, zielt darauf ab, den Zugang zu Verhütungsmitteln und die Auswahlmöglichkeiten für die Einwohner von Illinois zu erweitern.
- Expanded market access in Illinois for PHEXXI through pharmacist prescriptions
- Joins 30 other states allowing pharmacist-prescribed contraceptives, indicating strong market penetration potential
- Product can be prescribed regardless of BMI, expanding potential user base
- None.
Insights
Illinois law allowing pharmacists to prescribe PHEXXI from January 2026 expands market access, potentially boosting Evofem's sales in a meaningful state market.
The passage of Illinois House Bill 3489 represents a significant market access expansion for Evofem's PHEXXI contraceptive gel. Starting January 2026, Illinois pharmacists will be able to directly prescribe this non-hormonal contraceptive, removing a substantial barrier to access that currently requires physician visits.
This regulatory change positions Illinois as the 31st state (plus DC) to allow pharmacist-prescribed contraceptives, creating a more streamlined path to market for Evofem's product. From a commercial perspective, Illinois represents approximately 3.9% of the US female population, making this a meaningful market opportunity.
The expanded access is particularly valuable for PHEXXI given its differentiated position as a non-hormonal, on-demand contraceptive. This positioning addresses specific unmet needs for women who cannot or prefer not to use hormonal options. The timing of implementation (January 2026) means Evofem has adequate runway to prepare their commercial strategy to capitalize on this regulatory tailwind.
While this development won't have immediate revenue impact, it enhances PHEXXI's long-term commercial outlook by removing prescription barriers in a significant state market. This incremental improvement in accessibility aligns with broader industry trends toward increasing contraceptive access through pharmacy channels, potentially setting the stage for additional states to follow with similar legislation.
-- Passage of House Bill 3489 allows
-- Ensures a broader range of contraceptive choices is available to women state-wide --
"The newly ratified House Bill 3489 addresses a critical need by empowering pharmacists across
The enactment of this new law marks considerable progress for
House Bill 3489 was introduced by Illinois State Representative Michelle Mussman; Senator Rachael Ventura was its Chief Senate Sponsor. Its passage positions
Women nationwide may also visit phexxi.com to learn more, connect with a healthcare provider and, if desired, obtain a prescription for PHEXXI.
Approved by the FDA in May 2020, PHEXXI prevents pregnancy without hormones. Notable features of the vaginal pH modulator include that:
- PHEXXI is administered vaginally, before each act of intercourse, providing a simple and discreet method of contraception and eliminating concerns about potential interactions with oral, injectable and topical medications;
- Unlike certain hormonal contraceptives, PHEXXI can be prescribed for and used by women with any body mass index (BMI); and
- PHEXXI was clinically demonstrated to increase sexual satisfaction in the pivotal Phase 3 AMPOWER trial.
About Evofem Biosciences
Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products, PHEXXI® (lactic acid, citric acid, and potassium bitartrate) and SOLOSEC® (secnidazole) 2g oral granules .
Evofem filed a preliminary proxy on July 24, 2025 regarding its planned Special Meeting of Stockholders at which stockholders of record may vote on a proposal to approve the transactions contemplated under the A&R Merger Agreement between the Company, Aditxt, Inc. (NASDAQ: ADTX) and Adifem, Inc., a wholly owned subsidiary of Aditxt. Under the A&R Merger Agreement, Adifem will merge with and into the Company, with Evofem surviving as a wholly owned subsidiary of Aditxt. A definitive proxy filing is expected in a few weeks.
PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc.
About PHEXXI
PHEXXI is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex.
Important Safety Information
- Rare cases (
0.36% ) of bladder and kidney infection have been reported. If you have a history of urinary tract problems that keep coming back, you should not use PHEXXI®. - Contact your healthcare provider if you are experiencing genitourinary side effects such as vaginal burning, itching, discharge, genital discomfort (including in male partners), yeast infection, urinary tract infection or bacterial vaginosis.
- PHEXXI does not protect against any sexually transmitted infections, including HIV.
- Avoid using PHEXXI with a vaginal ring.
- Avoid PHEXXI if you or your sexual partner is allergic to lactic acid, citric acid, potassium bitartrate, or any of the ingredients in PHEXXI. Stop using PHEXXI if you develop an allergic reaction.
For more information about PHEXXI, talk to your healthcare provider and see full Product Information .
Please report side effects by contacting Evofem Biosciences® toll-free at 1-833-EVFMBIO or contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
Forward-Looking Statements
This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated timing of the definitive proxy filing regarding the planned Special Meeting of Stockholders. The closing of the transactions with Evofem, Aditxt and Adifem, Inc., contemplated by the A&R Merger Agreement are subject to several conditions including, but not limited to, 1) approval of the transactions by a majority of the combined voting power of Evofem's E-1 and Common Stock, voting together as a single class, at a meeting where quorum is present, and 2) Aditxt raising sufficient capital to fund its closing obligations, notably a cash payment of approximately
No Offer or Solicitation
This release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transactions under the A&R Merger Agreement. This release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.
Connect with Us
Media
media@evofem.com
Investors and Prospective Partners
Amy Raskopf, Chief Business Development Officer
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
Join the Dialogue | |
@evofem + @saundrapelletier | |
TikTok | @phexxi + @saundrapelletier |
@evofem, @phexxi + @saundrapelletier | |
X | @evofem + @SaundraCEO |
@evofem + @phexxi | |
View original content to download multimedia:https://www.prnewswire.com/news-releases/illinois-pharmacists-can-prescribe-phexxi-starting-january-2026-under-newly-passed-law-302535796.html
SOURCE Evofem Biosciences, Inc.
FAQ
When will pharmacists in Illinois be able to prescribe PHEXXI?
What makes PHEXXI (EVFM) different from other contraceptives?
How many states now allow pharmacists to prescribe contraceptives like PHEXXI?
What are the key benefits of PHEXXI mentioned in the Illinois legislation announcement?
How can women outside Illinois get access to PHEXXI (EVFM)?
